GenomeWeb – October 2022

Almaden Genomics, a company with roots in an IBM Research laboratory in Silicon Valley, will publicly launch Tuesday with the introduction of g.nome, a cloud-based software platform meant to improve genomic research and discovery by simplifying the process of building and managing bioinformatics workflows.

Almaden is being unveiled by Catalyze Dallas, a firm that purchases technology assets from Fortune 100 companies to accelerate commercialization. Catalyze Dallas, which is funded by wealthy individuals looking for new investments, bought the intellectual property that became Almaden from IBM last month. Terms were not disclosed.